Search research articles
Contact Us
Filters
Showing results (91-100 of 102) with videos related to
Page
of 11
Sort By:
Iscience
|
November 15, 2023
TMEM106B reduction does not rescue GRN deficiency in iPSC-derived human microglia and mouse models
Sara L Dominguez, Benjamin I Laufer, Arundhati Sengupta Ghosh, et al.
Cell Reports. Medicine
|
October 8, 2024
An RNA damage response network mediates the lethality of 5-FU in colorectal cancer
Jung-Kuei Chen, Karl A Merrick, Yi Wen Kong, et al.
Nature Cell Biology
|
June 21, 2016
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia
Robert S Banh, Caterina Iorio, Richard Marcotte, et al.
Cell Reports
|
July 5, 2016
NeuCode Proteomics Reveals Bap1 Regulation of Metabolism
Joshua M Baughman, Christopher M Rose, Ganesh Kolumam, et al.
Nature Communications
|
November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
Journal of Oncology Practice
|
August 15, 2013
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry
Jason A Efstathiou, Deborah S Nassif, Todd R McNutt, et al.
Nature Biotechnology
|
October 19, 2023
Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types
Hem R Gurung, Amy J Heidersbach, Martine Darwish, et al.
American Journal of Hematology
|
January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
Elisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
Journal of Medicinal Chemistry
|
January 5, 2024
PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Journal of Medicinal Chemistry
|
May 21, 2025
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models"
Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 102) with videos related to
Sort By:
Page
of 11
Iscience
|
November 15, 2023
TMEM106B reduction does not rescue GRN deficiency in iPSC-derived human microglia and mouse models
Sara L Dominguez, Benjamin I Laufer, Arundhati Sengupta Ghosh, et al.
Cell Reports. Medicine
|
October 8, 2024
An RNA damage response network mediates the lethality of 5-FU in colorectal cancer
Jung-Kuei Chen, Karl A Merrick, Yi Wen Kong, et al.
Nature Cell Biology
|
June 21, 2016
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia
Robert S Banh, Caterina Iorio, Richard Marcotte, et al.
Cell Reports
|
July 5, 2016
NeuCode Proteomics Reveals Bap1 Regulation of Metabolism
Joshua M Baughman, Christopher M Rose, Ganesh Kolumam, et al.
Nature Communications
|
November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
Journal of Oncology Practice
|
August 15, 2013
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry
Jason A Efstathiou, Deborah S Nassif, Todd R McNutt, et al.
Nature Biotechnology
|
October 19, 2023
Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types
Hem R Gurung, Amy J Heidersbach, Martine Darwish, et al.
American Journal of Hematology
|
January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
Elisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
Journal of Medicinal Chemistry
|
January 5, 2024
PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Journal of Medicinal Chemistry
|
May 21, 2025
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models"
Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Page
of 11